The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

The FDA has approved the interferon gamma-blocking antibody emapalumab -lzsg (Gamifant) for the treatment of macrophage activation syndrome (MAS) in known or suspected Still disease.

FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate manufacturer in place.

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease.

The antibody-based drug Andembry is the first to target factor XIIa, a protein responsible for swelling in people with this rare genetic disorder.

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

When Joe DeMayo’s donated kidney started to fail earlier than expected, he didn’t know that the drug he was taking could’ve left him vulnerable — and that one of the most formidable drug ...

FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease ...

MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with ...

On June 18, the U.S. Food and Drug Administration (FDA) approved the first medicine to prevent HIV that only has to be taken twice a year. People who are at high risk for HIV can now take the ...

The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo.

FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still’s disease ...